Back to search

University of British Columbia

Targeting DNA damage repair with novel DNA-PK inhibitor, BCCA7693 to delay krasg12c inhibitor resistance: balancing cell intrinsic efficacy and immune antagonism

Abstract

dc:description

Treatment resistance remains a major barrier in the treatment of KRAS-mutated lung cancers and despite the effectiveness of combinatorial strategies, including MEK inhibitor trametinib and KRASG¹²C inhibitor adagrasib, at suppressing MAPK signalling and slowing tumour growth, the emergence of drug resistance demands a refined approach that targets oncogenic pathways at multiple nodes. Genomic instability is gaining recognition as a driver of resistance, particularly through repair of fragmented DNA, which probably occurs mainly via the non-homologous end joining pathway (NHEJ) and promotes the survival of cells that can bypass the effects of targeted inhibitors. Our group has developed a novel small molecule inhibitor (BCCA7693) of DNA-PK, a key component of NHEJ, which we have found increases the efficacy of adagrasib in monolayers and murine models in a context dependent manner. Using a panel of murine lung cancer cell lines, representing a spectrum of immunogenicity, we demonstrated that BCCA7693 + adagrasib increases genomic stress via the accumulation of micronuclei (MN). Crucially, our in vitro experiments revealed a lack of consistent correlation between MN accumulation and growth inhibition, suggesting that the consequence of genomic instability is context dependent. In vivo, BCCA7693 significantly delayed adagrasib resistance, particularly when combined with dual MAPK suppression (adding trametinib) in less immunogenic models. However, these effects followed a distinct survival hierarchy and did not reliably translate to improved survival in all contexts. In ‘immune hot’ models, the addition of BCCA7693 provided negligible survival advantages and actually diminished the benefit of PD-1 blockade. Spatial analysis revealed that this antagonism is linked to a CD8+ cell excluded phenotype, where cells are sequestered at the tumour margin and prevented from infiltrating the core. We conclude DNA-PK inhibition with BCCA7693 as a plausible resistance delaying agent, however the underlying immune context is what determines if its addition helps or antagonizes immunotherapies.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Interdisciplinary Oncology
Grantor dc:publisher
University of British Columbia
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Teymori, Sevin
Contributors dc:contributor
  • Minchinton, Andrew

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/95199

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Teymori, Sevin. Targeting DNA damage repair with novel DNA-PK inhibitor, BCCA7693 to delay krasg12c inhibitor resistance: balancing cell intrinsic efficacy and immune antagonism. master's thesis, University of British Columbia, 2026. http://hdl.handle.net/2429/95199